Multiple sclerosis pathology during early and late disease phases: Pathogenic and clinical relevance

Immune Regulation and Immunotherapy in Autoimmune Disease

Volumn , Issue , 2007, Pages 214-264

  Lucchinetti, Claudia F ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650178901     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-36003-4_12     Document Type: Chapter

References (217)

1. Aboul-Enein, F., Lassmann, H. (2005) Mitochondrial damage and histiotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease. Acta Neuropathol. (Berl.) 109:49-55.
2. Aboul-Enein, F., Rauschka, H., Kornek, B., et al. (2003) Preferential loss of myelinassociated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J. Neuropathol. Exp. Neurol. 62 (1) 25-33.
3. Aktas, O., Smorodchenko, A., Brocke, S., Infante-Duarte, C., Topphoff, US., Vogt, J., Prozorovski, T., Meier, S., Osmanova, V., Pohl, E., Bechmann, I., Nitsch, R., Zipp, F. (2005) Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46 (3) 421-432.
4. Allen, I., McKeown, S. (1979) A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J. Neurosci. 41:81-91.
5. Allen, I. V., Glover, G., Anderson, R. (1981) Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis. Acta Neuropathol. (Berl.) Suppl 7:176-181.
6. Allen, I. V., McQuaid, S., Mirakhur, M., Nevin, G. (2001) Pathological abnormalities in the normal-appearing white matter in multiple sclerosis. Neurol. Sci. 22 (2) 141-144.
7. Amiry-Moghaddam, M., Otsuka, T., Hurn, P. D., et al. (2003) An alpha-syntrophindependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain. Proc. Natl. Acad. Sci. U S A 100 (4) 2106-2111.
8. Andrews, H. E., Nichols, P. P., Bates, D., Turnbull, D. M. (2005) Mitochondrial dysfunction plays a key role in progressive axonal loss in multiple sclerosis. Med. Hypotheses 64:669-677.
9. Anthony, D. C., Ferguson, M. K., Matyzak, K. M., et al. (1997) Differential matrix metalloproteinase expression in cases of MS and stroke. Neuropathol. Appl. Neurobiol. 23:406-415.
10. Antony, J. M., van Marle, G., Opii, W., et al. (2004) Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendorcyte death and demyelination. Nat. Neurosci. 7:1088-1095.
11. Babbe, H., Roers, A., Waisman, A., et al. (2000) Clonal expansion of CD8 (+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192:393-404.
12. Baranzini, S. E., Jeongk, M. C., Butunol C., et al. (1999) B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J. Immunol. 163:5133-5144.
13. Barnett, M. H., Prineas, J. W. (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55 (4) 458-468.
14. Barres, B., Schmid, R., Sendtner, M., Raff, M. (1993) Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 118:283-295.
15. Bitsch, A., Bruhn, H., Vougioukas, V., et al. (1999) Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am. J. Neuroradiol. 20 (9) 1619-1627.
16. Bitsch, A., Kuhlmann, T., Da Costa, C., et al. (2000a) Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 29 (4) 366-375.
17. Bitsch, A., Schuchardt, J., Bunkowski, S., et al. (2000b) Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 123 (Pt 6) 1174-1183.
18. Bo, L., Dawson, T., Wesselingh, S., et al. (1994) Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36:778-786.
19. Bo, L., Vedeler, C., Nyland, H., et al. (2003a) Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 9 (4) 323-331.
20. Bo, L., Vedeler, C., Nyland, H., et al. (2003b) Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 62 (7) 723-732.
21. Bolanos, J., Almeida, A., Stewart, V., et al. (1997) Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J. Neurochem. 68:2227-2240.
22. Bonetti, B., Pohl, J., Gao, Y. L., Raine, C. S. (1997) Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. J. Immunol. 159 (11) 5733-5741.
23. Booss, J., Esiri, M. M., Tourtellotte, W. W., Mason, D. Y. (1983) Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J. Neurol. Sci. 62:219-232.
24. Boven, L. A., Van Meurs, M., Van Zwam, M., et al. (2006) Mylin-laden macropahges are anti-inflammatory consistent with foam cells in multiple sclerosis. Brain 129:517-526.
25. Bozzali, M., Cercignani, M., Sormani, M. P., et al. (2002) Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am. J. Neuroradiol. 23:985-988.
26. Brenner, T., Brocke, S., Szafer, F., et al. (1997) Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J. Immunol. 158:2940-2946.
27. Brown, G., Bolanos, J., Heales, S., Clark, J. (1995) Nitric oxide produced by activated astrocytes rapidly and reversibly inhibits cellular respiration. Neurosci. Lett. 193:201-204.
28. Brown, G. C., Borutaite, V. (2002) Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free Radic. Biol. Med. 33:1440-1450.
29. Bruck, W., Porada, P., Poser, S., et al. (1995) Monocyte-macrophage differentiation in early multiple sclerosis lesions. Ann. Neurol. 38:788-796.
30. Brueck, W., Schmied, M., Suchanek, G., et al. (1994) Oligodendrocytes in the early course of multiple sclerosis. Ann. Neurol. 35:65-73.
31. Chang, A., Tourtellotte, W. W., Rudick, R., Trapp, B. D. (2002) Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 346 (3) 165-173.
32. Chen, C., Ro, L., Chang, C., et al. (1996) Serial MRI studies in pathologically verified Balo's concentric sclerosis. J. Comput. Assist. Tomogr. 20:732-735.
33. Christians, E. S., Yan, L. J., Benjamin, I. J. (2002) Heat shock factor 1 and heat shock proteins: critial partners in portection against acute cell injury. Crit. Care Med. 30:S43-S50.
34. Cifelli, A., Arridge, M., Jezzard, P., et al. (2002) Thalamic neurodegeneration in multiple sclerosis. Ann. Neurol. 52 (5) 650-653.
35. Ciccarelli, O., Werring, D. J., Wheeler-Kingshott, C. A., et al. (2001) Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology 56:926-933.
36. Coles, A. J., Wing, M. G., Molyneux, P., et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46 (3) 296-304.
37. Coles, A., Deans, J., Compston, A. (2004) Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin. Neurol. Neurosurg. 106 (3) 270-274.
38. Confavreux, C., Vukusic, S., Moreau, T., Adeleine, P. (2000) Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343:1430-1438.
39. Courville, C. (1970) Concentric sclerosis. In: Bruyn PVaG (ed) Handbood of Clinical Neurology. Amsterdam, Elsevier, pp 437-451.
40. Cowden, W., Cullen, F., Staykova, M., Willenborg, D. (1998) Nitric oxide is a potential down-regulating molecule in autoimmune disease: inhibition of nitric oxide production renders PVG rats highly susceptible to EAE. J. Neuroimmunol. 88:1-8.
41. Cox, A., Coles, A., Antoun, N., Malik, O., Lucchinnetti, C., Compston, A. (2005) Recurrent myelitis and optic neuritis in a 29-year-old woman. [Case Reports]. Clinical Conference. Lancet Neurology 4 (8) 510-516.
42. Craner, M. J., Lo, A. C., Blcak, P. A., Wazxman, S. G. (2003) Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. Brain 126:1552-1561.
43. Craner, M. J., Newcombe J., Black J. A., et al. (2004) Molecular changes in neurons in MS: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca++ exchanges. Proc. Natl. Am. Soc. USA 101:8168-8173.
44. Cross, A., Trotter, J., Lyons, J. (2001) B cells and antibodies in CNS demyelinating disease. J. Neuroimmunol. 112:1-14.
45. Cuzner, M., Gveric, D., Strand, C. (1996) The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55:1194-1204.
46. Dawson, J. (1916) The histology of dissseminated sclerosis. Trans. R. Soc. Edinb. 50:517-740.
47. De Groot, C., Ruuls, S., Theeuwes, J., et al. (1997) Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 56:10-20.
48. Dehmeshki, J., Chard, D. T., Leary, S. M., et al. (2003) The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. J. Neurol. 250:67-74.
49. DeLuca, G. C., Ebers, G. C., Esiris, M. M. (2004) Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 127:1009-1018.
50. Diemel, L. T., Copelman, C. A., Cuzner, M. L. (1998) Macrophages in CNS remyelination: friend or foe? Neurochem. Res. 23 (3) 341-347.
51. Dowling, P., Shang, G., Raval, S., et al. (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 184 (4) 1513-1518.
52. D'Souza, S., Bonetti, B., Balasingam, V., et al. (1996) Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med. 184:2361-2370.
53. Dutta, R., McDonough, J., Yin, X., et al. (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59:478-489.
54. Esiri, M. M. (1977) Immunoglobulin-containing cells in multiple sclerosis plaques. Lancet 2:478.
55. Evangelou, N. (2003) Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2003;123:1845-1849.
56. Evangelou, N., Esiri, M. M., Smith, S., et al. (2000) Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann. Neurol. 47 (3) 391-395.
57. Evangelou, N., Konz, D., Esiri, M. M., et al. (2001) Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 124:1813-1820.
58. Ferguson, B., Matyszak, M. K., Esiri, M. M., Petty, V. H. (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399.
59. Filippi, M. (2003) Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126:433-437.
60. Filippi, M., Campi, A., Dousset, V., et al. (1995) A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 45:478-482.
61. Filippi, M., Rocca, M., Martino, G., et al. (1998) Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann. Neurol. 43:809-814.
62. Flavin, M. P., Coughlin, K., Ho, L. T. (1997) Soluble macrophage factors trigger apoptosis in cultured hippocampal neurons. Neuroscience 80:437-448.
63. Flavin, M. P., Zhao, G., Ho, L. T. (2000) Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro. Glia 29:347-354.
64. Foote, A. K., Blakemore, W. F. (2005) Inflammation stimulates remyelination in areas of chronic demyelination. Brain 128:528-539.
65. Forstermann, U., Kleinert, H. (1995) Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch. Pharmacol. 352:351-364.
66. Franklin, R. J. (2002) Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 3 (9) 705-714.
67. Garbern, J., Spence, A., Alvord, E. (1986) Balo's concentric demyelination diagnosed premortem. Neurology 36:1610-1614.
68. Garthwaite, G., Goodwin, D. A., Batchelor, A. M., et al. (2002) Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve. Neuroscience 109:145-155.
69. Gay, F., Drye, T., Dick, G., Asiti, N. (1997) The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis: identification and characterization of primary demyelinating lesion. Brain 120:1461-1483.
70. Genain, C. P., Cannella, B., Hauser, S. L., Raine, C. S. (1999) Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5 (2) 170-175.
71. Gendelman, H. E., Pezeshkpour, G. H., Pressman, N. J., et al. (1985) A quantitation of myelin-associated glycoprotein and myelin basic protein loss in different demyelinating diseases. Ann. Neurol. 18 (3) 324-328.
72. Geurts, J. J., Wolswijk, G., Bo, L., et al. (2003) Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 126:1755-1766.
73. Gharagozloo, A., Poe, L., Collins, G. (1994) Antemortem diagnosis of Balo concentric sclerosis: correlative MR imaging and pathologic features. Radiology 191:817-819.
74. Gilgun-Sherki, Y., Panet, H., Melamed, E., Offen, D. (2003) Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res. 989:196-204.
75. Giovannoni, G., Heales, S., Land, J., Thompson, E. (1998) The potential role of nitric oxide in multiple sclerosis. Mult. Scler. 4:212-216.
76. Graumann, U., Reynolds, R., Steck, A. J., Schaeren-Wiemers, N. (2003) Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 13 (4) 554-573.
77. Griot, C., Vandevelde, M., Richard, A., et al. (1990) Selective degeneration of oligodendrocytes mediated by reactive oxygen species. Free Radic. Res. Commun. 11 (4-5) 181-193.
78. Grossman, R. I., Braffman, B. H., Brorson, J. R., et al. (1988) Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 169:117-122.
79. Hafler, D. A. (2004) Multiple sclerosis. J. Clin. Invest. 113 (6) 788-794.
80. Hafler, D. A., Slavik, J. M., Anderson, D. E., et al. (2005) Multiple sclerosis. Immunol. Rev. 204:208-231.
81. Hanemann, C., Kleinschmidt, A., Reifenberger, G., et al. (1993) Balo concentric sclerosis followed by MRI and positron emission tomography. Neuroradiology 35:578-580.
82. Haring, J. S., Pewe, L. L., Perlman, S. (2002) Bystander CD8 T cell-mediated demyelination after viral infection of the central nervous system. J. Immunol. 169:1550-1555.
83. Hayashi, T., Burks, J. S., Hauser, S. L. (1988) Expression and cellular localization of major histocompatibility complex antigens in active multiple sclerosis lesions. Ann. N. Y. Acad. Sci. 540:301-305.
84. Hendricks, J. J., Teunissen, C. E., de Vries, H. E., Dijkstra, C. D. (2005) Macrophages and neurodegeneration. Brain Res. Rev. 48:185-195.
85. Hill, K. E., Zollinger, L. V., Watt, H. E., et al. (2004) Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression, and association with myelin damage. J. Neuroimmunol. 151:171-179.
86. Hoftberger, R., Aboul-Enein, F., Brueck, W., et al. (2004) Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 14:43-50.
87. Hohlfeld, R. (1997) Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 120:865-916.
88. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. (1995) Interferon b-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 45:1277-1285.
89. Ingle, G. T., Stevenson, V. L., Miller, D. H., Thompson, A. J. (2003) Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 126:2528-2536.
90. Itoyama, Y., Sternberger, N. H., Webster, H. D., et al. (1980) Immunocytochemical observations on the distribution of myelin-associated glycoprotein and myelin basic protein in multiple sclerosis lesions. Ann. Neurol. 7:167-177.
91. Itoyama, Y., Webster, H. D., Sternberger, N. H., et al. (1982) Distribution of papovavirus, myelin-associated glycoprotein, and myelin basic protein in progressive multifocal leukoencephalopathy lesions. Neurology 11 (4) 396-407.
92. Jiang, F., Levison, S., Wood, T. (1999) Ciliary neurotrophic factor induces expression of the IGF type I receptor and FGF receptor 1 mRNAs in adult rat brain oligodendrocytes. J. Neurosci. Res. 57:447-457.
93. Jung, J., Bhat, R., Preston, G., et al. (1994) Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc. Natl. Acad. Sci. USA 91:13052-13056.
94. Jurewicz, A., Biddison, W. E., Antel, J. P. (1998) MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J. Immunol. 160:3056-3059.
95. Kapoor, R., Davies, M., Blaker, P., et al. (2003) Blockers of sodium and calcium entry protect axons from nitric-oxide medaited degeneration. Ann. Neurol. 53 (2) 174-180.
96. Karaarslan, E., Altintas, A., Senol, U., et al. (2001) Balo's concentric sclerosis: clinical and radiologic features of five cases. AJNR Am. J. Neuroradiol. 22 (7) 1362-1367.
97. Keegan, M., Konig, F., McClelland, R., et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366(9485):579-582.
98. Kerschensteiner, M., Gallmeier, E., Behrens, L., et al. (1999) Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: a neuroprotective role for inflammation? J. Exp. Med. 189:865-870.
99. Kidd, D., Barkhof, F., McConnell, R., et al. (1999) Cortical lesions in multiple sclerosis. Brain 122 (1) 17-26.
100. Kivisakk, P., Mahad, D., Callahan, M. K., et al. (2003) Cerebrospinal fluid central memory T-cells traffic through choroid plexus and meninges. Proc. Natl. Acad. Sci. U S A 100:8389-8394.
101. Kornek, B., Lassmann, H. (1999) Axonal pathology in multiple sclerosis: a historical note. Brain Pathol. 9:651-656.
102. Kornek, B., Storch, M. K., Weissert, R., et al. (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157 (1) 267-276.
103. Korte, J., Born, E., Vos, L., et al. (1994) Balo concentric sclerosis: MR diagnosis. AJNR Am. J. Neuroradiol. 15:1284-1285.
104. Kotter, M. R., Setzu, A., Sim, F. J., et al. (2001) Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 35 (3) 204-212.
105. Kuroiwa, Y. (1982) Clinical and epidemiological aspects of multiple sclerosis in Japan. Jpn. J. Med. 21 (2) 135-140.
106. Kutzelnigg, A., Lucchinetti, C., Stadelmann, C., et al. (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 (11) 2705-2712.
107. Lassmann, H. (1983) Comparative neuropathology of chronic experimental allergic encephalomyelitis and mulitple sclerosis. Springer Schriftenr. Neurol. 25:1-135.
108. Lassmann, H. (2003a) Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J. Neurol. Sci. 206 (2) 187-191.
109. Lassmann, H. (2003b) Axonal injury in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 74:695-697.
110. Lassmann, H., Wisniewski, H. M. (1979) Chronic relapsing experimental allergic encephalomyelitis: morphological sequence of myelin degradation. Brain Res. 169:357-368.
111. Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106-2112.
112. Lennon, V. A., Kryzer, T. J., Pittock, S. J., et al. (2005) IgG marker of optic-spinal MS binds to the aquaporin 4 water channel. J. Exp. Med. 202 (4) 473-477.
113. Linberg, R. L., De Groot, C. J., Montagne, L., et al. (2001) The expression profile of matrix metalloproteinases and their inhibitors in lesions and normal appearing white matter of multiple sclerosis. Brain 124:1743-1753.
114. Linington, C., Bradl, M., Lassmann, H., et al. (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 130:443-454.
115. Liu, J., Zhao, M., Brosnan, C., Lee, S. (2001) Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am. J. Pathol. 158:2057-2066.
116. Lock, C., Hermans, G., Pedotti, R., et al. (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8:500-508.
117. Louis, J., Magal, E., Takayama, S., Varon, S. (1993) CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science 259:689-692.
118. Lu, F., Selak, M., O'Connor, J., et al. (2000) Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J. Neurol. Sci. 177:95-103.
119. Lu, W., Bhasin, M., Tsirka, S. E. (2002) Involvment of tissue plasminogen activator in onset and effector phases of experimental allergic encpehalomyelitis. J. Neurosci. 22:10781-10789.
120. Lublin, F. D., Baier, M., Cutter, G. (2003) Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61:1528-1532.
121. Lucchinetti C., Bruck W. (2004) The pathology of primary progressive multiple sclerosis. Mult. Scler. 10(Suppl 1):S23-S30.
122. Lucchinetti, C. F., Brueck, W., Rodriguez, M., et al. (1999) A quantitative study on the fate of the oligodendrocyte in multiple sclerosis lesions: a study of 113 cases. Brain 122:2279-2295.
123. Lucchinetti, C. F., Bruck, W., Parisi, J., et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:707-717.
124. Lucchinetti, C. F., Mandler, R. N., McGavern, D., et al. (2002a) A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125 (Pt 7) 1450-1461.
125. Lucchinetti, C., Mandler, R., Weinshenker, B., et al. (2002b) Humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Neurology 54(Suppl 3):A259.
126. Lucchinetti, C. F., Bruck, W., Lassmann, H. (2004) Evidence for pathogenic heterogeneity in multiple sclerosis. Ann. Neurol. 56:308.
127. Ludwin, S., Johnson, E. (1981) Evidence of a "dying back" gliopathy in demyelinating disease. Ann. Neurol. 9:301-305.
128. Ludwin, S. K. (1990) Oligodendrocyte survival in wallerian degeneration. Acta Neuropathol. (Berl.) 80:184-191.
129. Lumsden, C. (1970) The neuropathology of multiple sclerosis. In: Vinken P, Bruyn G (eds) Handbook of Clinical Neurology. New York, Elsevier, pp 217-309.
130. Mahad, D. J., Trebst, C., Kivisakk, P., et al. (2004) Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 63 (3) 262-273.
131. Mantovani, A., Sica, A., Sozzani, S., et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25:677-686.
132. Marburg, O. (1906) Die sogenannte "akute Multiple Sklerose." J. Psychiatr. Neurol. 27:211-312.
133. Matute, C., Alberdi, E., Domercq, M., et al. (2001) The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci. 24 (4) 224-230.
134. Mayer, M., Bhakoo, K., Noble, M. (1994) Ciliary Neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. Development 120:143-153.
135. McCombe, P. A., Nickson, I., Tabi, Z., Pender, M. P. (1996) Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of V beta 8.2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of V beta 8.2+ cells. J. Neuroimmunol. 70 (2) 93-101.
136. McKeown, S. R., Allen, V. (1978) The cellular origin of lysosomal enzymes in the plaque of multiple sclerosis: a combined histological and biochemical study. Neuropathol. Appl. Neurobiol. 4:471-482.
137. Mehta, P. D., et al. (1981) Bound antibody in multiple sclerosis brains. J. Neurol. Sci. 49:91-98.
138. Merrill, J. E., Scolding, N. J. (1999) Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. Neuropathol. Appl. Neurobiol. 25 (6) 435-458.
139. Mews, I., Bergmann, M., Bunkowski, S., et al. (1998) Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult. Scler. 4 (2) 55-62.
140. Miller, D. H., Rudge, P., Johnson, G., et al. (1988) Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 111:927-939.
141. Moalem, G., Leibowitz-Amit, R., Yoles, E., et al. (1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5 (1) 49-55.
142. Molyneux, P. D., Kappos, L., Polman, C., et al. (2000) The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis: European Study Group on interferon beta-1b in secondary progressive multiple sclerosis. Brain 123 (Pt 11) 2256-2263.
143. Mosser, D. M. (2003) The many faces of macrophage activation. J. Leukoc. Biol. 73:209-212.
144. Murray, P., McGavern, D., Lin, X., et al. (1998) Perforin-dependent neurologic injury in a viral model of multiple sclerosis. J. Neurosci. 18:7306-7314.
145. Neumann, H., Medana, I. M., Bauer, J., Lassmann, H. (2002) Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 25 (6) 313-319.
146. Nitsch, R., Pohl, E. E., Smorodchenko, A., Infante-Duarte, C., Aktas, O., Zipp, F. (2004) Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue. Journal of Neuroscience 24 (10) 2458-2464.
147. Oleszak, E. L., Zaczynska, E., Bhattacharjee, M., et al. (1998) Indcible nitric oxide synthase and nitrotyrosine are dound in monocytes/macropahges and/or astrocytes in acute, but not in chronic multiple sclerosis. Clin. Diagn. Lab. Immunol. 5:438-445.
148. Onodera, H., Nakashima, I., Fujihara, K., et al. (1999) Elevated plasma level of plasminogen activator inhibitor-1 (PAI01) in patients with relapsing-remitting multiple sclerosis. Tohoku J. Exp. Med. 189:259-265.
149. Owens, G. P., Kraus H., Burgoon, M. P., et al. (1998) Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann. Neurol. 43:236-243.
150. Owens, G. P., Ritchie, A. M., Burgoon, M. P., et al. (2003) Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal flu. J. Immunol. 171:2725-2733.
151. Ozawa, K., Suchanek, G., Breitschopf, H., et al. (1994) Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117:1311-1322.
152. Pelletier, D., Nelson, S. J., Oh, J., et al. (2003) MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy. J. Neurol. Neurosurg. Psychiatry 74:950-952.
153. Peterson, J. W., Bo, L., Mork, S., et al. (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50 (3) 389-400.
154. Pitt, D., Werner, P., Raine, C. S. (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6 (1) 67-70.
155. Pittock, S. J., Mayr, W. T., McClelland, R. L., et al. (2004) Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 62 (1) 51-59.
156. Pittock, S. J., McClelland, R. L., Achenbach, S. J. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis, et al. (2005) Clinical course, pathologic correlations and outcome of biopsy proven inflammatory demyelinating disease. J. Neurol. Neurosurg. Psychiatry 767 (12) 1693-1697.
157. Pittock, S. J., Lennon, V. A., Krecke, K., et al. (2006) Brain abnormalities in patients with neuromyelitis optica. Arch. Neurol. 63:390-396.
158. Prat, A., Antel, J. (2005) Pathogenesis of multiple sclerosis. Curr. Opin. Neurol. 18:225-230.
159. Prineas, J. (1985) The neuropathology of multiple sclerosis. In: Vinken P, Bruyn G, Klawans H (eds) Handbook of Clinical Neurology. New York, Elsevier Science, pp 213-257.
160. Prineas, J. W., Graham, J. S. (1981) Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann. Neurol. 10:149-158.
161. Prineas, J. W., Wright, R. G. (1978) Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. 38 (4) 409-421.
162. Prineas, J. W., Barnard, R. O., Kwon, E. E., et al. (1992a) Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol. 33:137-151.
163. Prineas, J. W., Barnard, R. O., Revesz, T., et al. (1992b) Multiple sclerosis: pathology of recurrent lesions. Brain 116 (Pt 3) 681-693.
164. Prineas, J. W., Kwon, E. E., Cho, E. S., et al. (2001) Immunopathology of secondaryprogressive multiple sclerosis. Ann. Neurol. 50 (5) 646-657.
165. Probert, L., Akassoglou, K., Pasparakis, M., et al. (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous systemspecific expression of tumor necrosis factor alpha. Proc. Natl. Acad. Sci. USA 92:11294-11298.
166. Qin, Y., et al. (1998) Clonal expansion and somatic hypermutation of V (H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 102:1045-1050.
167. Raine, C. S., Scheinberg, L., Waltz, J. M. (1981) Multiple sclerosis: oligodendrocyte survival and proliferation in an active established lesion. Lab. Invest. 45:534-546.
168. Raine, C. S., Cannella, B., Duijvestijn, A. M., Cross, A. H. (1990) Homing to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab. Invest. 63:476-489.
169. Redford, E. J., Kapoor, R., Smith, K. J. (1997) Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 120:2149-2157.
170. Revel, M., Valiente, E., Gray, F., et al. (1993) Concentric MR patterns in multiple sclerosis: report of two cases. J. Neuroradiol. 20 (4) 252-257.
171. Rivera-Quinones, C., McGavern, D., Schmelzer, J. D., et al. (1998) Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat. Med. 4 (2) 187-193.
172. Rocca, M. A., Iannucci, G., Rovaris, M., et al. (2003) Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions: a diffusion tensor MR study. J. Neurol. 250:456-460.
173. Rodriguez, M. (1985) Virus-induced demyelination in mice: "dying back" of oligodendrocytes. Mayo Clin. Proc. 60:433-438.
174. Rodriguez, M., Sheithauer, B. (1994) Ultrastructure of multiple sclerosis. Ultrastruct. Pathol. 18:3-13.
175. Rotola, A., Merlotti, I., Caniatti, L., et al. (2004) Human herpesvirus 6 infects the central nervous system of multiple sclerosis patients in the early stages of the disease. Mult. Scler. 10:348-354.
176. Rovaris, M., Bozzali, M., Santuccio, G., et al. (2001) In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 124:2540-2549.
177. Rovaris, M., Bozzali, M., Iannucci, G., et al. (2002) Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. Arch. Neurol. 59:1406-1412.
178. Sadahiro, S., Yoshikawa, H., Yagi, N., et al. (2000) Morphometric analysis of the myelinassociated oligodendrocytic basic protein-deficient mouse reveals a possible role for myelin-associated oligodendrocytic basic protein in regulating axonal diameter. Neuroscience 98 (2) 361-367.
179. Scolding, N. J., Jones, J., Compston, D. A., Morgan, B. P. (1990) Oligodendrocyte susceptibility to injury by T-cell perforin. Immunology 70:6-10.
180. Selmaj, K. W., Raine, C. S. (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23:339-346.
181. Selmaj, K., Brosnan, C. F., Raine, C. S. (1991a) Colocalization of
182. Selmaj, K., Cross, A. H., Farooq, M., et al. (1991b) Non-specific oligodendrocyte cytotoxicity mediated by soluble products of activated T cell lines. J. Neuroimmunol. 35:261-271.
183. Selmaj, K., Raine, C. S., Cannella, B., Brosnan, C. F. (1991c) Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87:949-954.
184. Selmaj, K., Brosnan, C. F., Raine, C. S. (1992) Expression of heat shock protein-65 by oligodendrocytes in vivo and in vitro: implications for multiple sclerosis. Neurology 42:795-800.
185. Sendtner, M., Carroll, P., Holtmann, B., et al. (1994) Ciliary neurotrophic factor. J. Neurobiol. 25:1436-1453.
186. Sharp, F. R., Bernaudin, M. (2004) HIF1 and oxygen sensing in the brain. Nat. Rev. Neurosci. 5:437-448.
187. Skulina, C., Schmidt, S., Dornmair, K., et al. (2004) Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. USA 101:2428.
188. Smith, K. J., Lassmann, H. (2002) The role of nitric oxide in multiple sclerosis. Lancet Neurol. 1 (4) 232-241.
189. Smith, K. J., Kapoor, R., Hall, S. M., Davies, M. (2001) Electrically active axons degenerate when exposed to nitric oxide. Ann. Neurol. 49 (4) 470-476.
190. Smith, T., Groom, A., Zhu, B., Turski, L. (2000) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6 (1) 62-66.
191. Smith-Jensen, T., Burgoon, M. P., Anthony, J., et al. (2000) Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response. Neurology 54:1227-1232.
192. Sobel, R., Mitchell, M., Fondren, G. (1990) Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am. J. Pathol. 136:1309-1316.
193. Spiegel, M., Kruger, H., Hofmann, E., Kappos, L. (1989) MRI study of Balo's concentric sclerosis before and after immunosuppressant therapy. J. Neurol. 236:487-488.
194. Stadelmann, C., Kerschensteiner, M., Misgeld, T., et al. (2002) BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune cells and neuronal cells. Brain 125:75-85.
195. Stadelmann, C., Ludwin, S. K., Tabira, T., et al. (2004) Hypoxic preconditioning explains concentric lesions in Balo's type of multiple sclerosis. Submitted.
196. Stadelmann, C., Ludwin, S., Tabira, T., Guseo, A., Lucchinetti, C. F., Leel-Ossy, L., Ordinario, A. T., Bruck, W., Lassmann, H. (2005) Tissue preconditioning may explain concentric lesion in Balo's type of multiple sclerosis. Brain 128 (Pt 5) 979-987.
197. Storch, M. K., Piddlesden, S., Haltia, M., et al. (1998) Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 43 (4) 465-471.
198. Stys, P. K. (2004) Axonal degeneration in multiple sclerosis: is it time for neuroprotective strategies? Ann. Neurol. 55:601-603.
199. Thompson, A., Kermode, A., Wicks, D., et al. (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann. Neurol. 29:53-62.
200. Thompson, A. J., Polman, C. H., Miller, D. H., et al. (1997) Primary progressive multiple sclerosis. Brain 120:1085-1096.
201. Trapp, B. D., Peterson, J., Ransohoff, R. M., et al. (1998) Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:278-285.
202. Traugott, U. (1983) Multiple sclerosis: relevance of class I and class II MHC-expressing cells to lesion development. J. Neuroimmunol. 16:283-302.
203. Trebst, C., Sorensen, T., Kivisakk, P., et al. (2001) CCR1+/CCRf+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J. Pathol. 159:1701-1710.
204. Van der Goes, A., Boorsma, W., Hoekstra, K., et al. (2005) Determination of the sequential degradation of myelin proteins by macrophages. J. Neuroimmunol. 161:12-20.
205. Vass, K., Welch, W. J., Nowak, T. S. (1988) Localization of 70-kDa stress protein induction in gerbil brain after ischemia. Acta Neuropathol. (Berl.) 77:128-135.
206. Vercellino, M., Plano, F., Votta, B., et al. (2005) Grey matter pathology in multiple sclerosis. J. Neuropathol. Exp. Neurol. 64 (12) 1101-1107.
207. Vos, C. M., van Haastert, E. S., De Groot, C. J., et al. (2003) Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J. Neuroimmunol. 138:106-114.
208. Werner, P., Pitt, D., Raine, C. S. (2001) Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Neurol. 50 (2) 169-180.
209. Williamson, R. A., Burgoon, M. P., Owens, G. P., et al. (2001) Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc. Natl. Acad. Sci. USA 2001;98:1793-1798.
210. Wingerchuk, D. M., Hogancamp, W. F., O'Brien, P. C., Weinshenker, B. G. (1999) The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 (5) 1107-1114.
211. Wingerchuk, D., Pittock, S., Lennon, V., et al. (2005) Neuromyelitis optica diagnostic criteria revisited: validation and incorporation of the NMO-IgG serum autoantibody. Neurology 64:A38.
212. Wolswijk, G. (1998) Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurosci. 18 (2) 601-609.
213. Yamashita, T., Ando, Y., Obayashi, K., et al. (1997) Changes in nitrite and nitrate (NO2-/NO3-) levels in cerebrospinal fluid of patients with multiple sclerosis. J. Neurol. Sci. 153:32-34.
214. Yao, D. L., Webster, H., Hudson, L. D., et al. (1994) Concentric sclerosis (Balo): morphometric and in situ hybridization study of lesions in six patients. Ann. Neurol. 35:18-30.
215. Yoshikawa, H. (2001) Myelin-associated oligodendrocytic basic protein modulates the arrangement of radial growth of the axon and the radial component of myelin. Med. Electron Microsc. 34 (3) 160-164.
216. Youl, B. D., Kermode, A. G., Thompson, A. J., et al. (1991) Destructive lesions in demyelinating disease. J. Neurol. Neurosurg. Psychiatry 54:288-292.
217. Zhao, W., Tilton, R. G., Corbett, J. A., et al. (1996) Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. J. Neuroimmunol. 64:123-133.